SCHEMBL625782

SCHEMBL625782

[Dy+3].[Fe+3].[O-2].[O-2].[O-2]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971036 0.82
SCHEMBL5241197 0.82
SCHEMBL6688187 0.82
SCHEMBL15260 0.82
SCHEMBL9179591 0.82
SCHEMBL11438232 0.82
SCHEMBL11844591 0.82
SCHEMBL702028 0.82
SCHEMBL10833365 0.82
SCHEMBL11139608 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501476-A2 COMPOSITIONS AND METHODS FOR IN SITU AND IN VIVO IMAGING OF CELLS AND TISSUES Regents of the University of Michigan (US) 2005-02-02 EP claimed
US-20020122806-A1 Compositions and methods for in situ and in vivo imaging of cells and tissues MICHIGAN, REGENTS OF THE UNIVERSITY 2002-09-05 US claimed
WO-2002047537-A2 COMPOSITIONS AND METHODS FOR IN SITU AND IN VIVO IMAGING OF CELLS AND TISSUES REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2002-06-20 WO claimed
US-12378523-B2 Platelets as delivery agents CELLPHIRE, INC. (US) 2025-08-05 US disclosed
US-12290532-B2 Treatment of von Willebrand disease CELLPHIRE, INC. (US) 2025-05-06 US disclosed
US-20250064988-A1 MRI-AGENT LOADED PLATELET COMPOSITIONS AND METHODS OF PREPARING AND USING THE SAME CELLPHIRE, INC. (US) 2025-02-27 US disclosed
US-20250064856-A1 METHODS FOR ADMINISTERING PLATELET DERIVATIVE COMPOSITIONS TO SUBJECTS AFFLICTED WITH HERMANSKY PUDLAK SYNDROME OR BERNARD SOULIER SYNDROME CELLPHIRE, INC. (US) 2025-02-27 US disclosed
US-20250000908-A1 METHODS FOR PREPARING AND ADMINISTERING CRYOPRESERVED PLATELETS AND PLATELET DERIVATIVES LOADED WITH ANTI-CANCER DRUGS CELLPHIRE, INC. (US) 2025-01-02 US disclosed
WO-2024229305-A1 PLATELET DERIVATIVE COMPOSITIONS FOR USE IN CONTROLLING BLEEDING IN A SUBJECT CELLPHIRE, INC. (US) 2024-11-07 WO disclosed
US-20240307453-A1 METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS CELLPHIRE, INC. (US) 2024-09-19 US disclosed
WO-2024192173-A1 HLA-CHARACTERIZED PLATELET DERIVATIVE COMPOSITIONS, AND METHODS OF MAKING, SELECTING AND USING SUCH COMPOSITIONS CELLPHIRE, INC. (US) 2024-09-19 WO disclosed
EP-1501476-A2 COMPOSITIONS AND METHODS FOR IN SITU AND IN VIVO IMAGING OF CELLS AND TISSUES Regents of the University of Michigan (US) 2005-02-02 EP disclosed
EP-1436421-A2 METHODS FOR DETECTING OVARIAN CANCER MOUNT SINAI HOSPITAL (CA) 2004-07-14 EP disclosed
WO-2004029285-A2 METHODS FOR DETECTING ENDOCRINE CANCER MOUNT SINAI HOSPITAL (CA) 2004-04-08 WO disclosed
WO-2004021008-A2 METHODS FOR DETECTING BREAST AND OVARIAN CANCER MOUNT SINAI HOSPITAL (CA) 2004-03-11 WO disclosed
WO-2004021009-A2 METHODS FOR DETECTING ENDOCRINE CANCER USING KALLIKREIN 13 (KLK13) AS A BIOMARKER MOUNT SINAI HOSPITAL (CA) 2004-03-11 WO disclosed
WO-2003033731-A2 METHODS FOR DETECTING OVARIAN CANCER MOUNT SINAI HOSPITAL (CA) 2003-04-24 WO disclosed
WO-2003034068-A1 LOCALIZATION OF DISORDERS ASSOCIATED WITH KALLIKREINS MOUNT SINAI HOSPITAL (CA) 2003-04-24 WO disclosed
US-20020122806-A1 Compositions and methods for in situ and in vivo imaging of cells and tissues MICHIGAN, REGENTS OF THE UNIVERSITY 2002-09-05 US disclosed
WO-2002047537-A2 COMPOSITIONS AND METHODS FOR IN SITU AND IN VIVO IMAGING OF CELLS AND TISSUES REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2002-06-20 WO disclosed